PriceTargets.com logo

InnovAge - INNV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.65
  • Forecasted Upside: -9.52 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.35 As of 12/2/2022 10:00 PM ET
▲ +0.15 (2.08%)

This chart shows the closing price for INNV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New InnovAge Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INNV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INNV

Analyst Price Target is $6.65
▼ -9.52% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for InnovAge in the last 3 months. The average price target is $6.65, with a high forecast of $10.00 and a low forecast of $3.90. The average price target represents a -9.52% upside from the last price of $7.35.

This chart shows the closing price for INNV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in InnovAge.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/23/2022The Goldman Sachs GroupBoost TargetNeutral$6.00 ➝ $8.00
11/16/2022CitigroupBoost Target$5.00 ➝ $8.00
9/15/2022BarclaysLower TargetEqual Weight$6.00 ➝ $5.00
5/16/2022Robert W. BairdDowngradeOutperform ➝ Neutral$6.00 ➝ $5.00
5/11/2022Piper SandlerLower Target$5.00 ➝ $3.90
4/20/2022Piper SandlerDowngradeNeutral ➝ Underweight$4.00 ➝ $5.00
12/27/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$15.00 ➝ $4.00
12/23/2021BarclaysDowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.50
12/23/2021Piper SandlerDowngradeOverweight ➝ Neutral$14.00 ➝ $4.00
12/17/2021JPMorgan Chase & Co.Initiated CoverageNeutral$10.00
11/10/2021Piper SandlerLower TargetOverweight$20.00 ➝ $14.00
10/4/2021Robert W. BairdReiterated RatingBuy
9/29/2021CitigroupDowngradeBuy ➝ Neutral$30.00 ➝ $8.00
9/22/2021William BlairDowngradeOutperform ➝ Market Perform
9/22/2021Piper SandlerReiterated RatingOverweight$31.00 ➝ $20.00
9/9/2021CowenInitiated CoverageMarket Perform$17.00
8/12/2021BarclaysUpgradeEqual Weight ➝ Overweight$26.00 ➝ $19.00
7/19/2021The Goldman Sachs GroupLower TargetBuy$30.00 ➝ $28.00
5/27/2021Robert W. BairdInitiated CoverageOutperform$27.00
3/29/2021CitigroupInitiated CoverageBuy$30.00
3/29/2021William BlairInitiated CoverageOutperform
3/29/2021BarclaysInitiated CoverageEqual Weight$26.00
3/29/2021Piper SandlerInitiated CoverageOverweight$31.00
3/29/2021The Goldman Sachs GroupInitiated CoverageBuy$32.00
11/15/2019HC WainwrightReiterated RatingBuy$5.00
9/17/2019HC WainwrightReiterated RatingBuy$5.00
5/21/2019HC WainwrightInitiated CoverageBuy
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2022
  • 4 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
10/5/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2022

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

InnovAge logo
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. As of June 30, 2022, it served approximately 6,650 PACE participants in the United States; and operates 18 PACE centers in Colorado, California, New Mexico, Pennsylvania, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.
Read More

Today's Range

Now: $7.35
Low: $7.11
High: $7.60

50 Day Range

MA: $6.13
Low: $4.62
High: $7.35

52 Week Range

Now: $7.35
Low: $3.39
High: $9.15

Volume

34,500 shs

Average Volume

201,211 shs

Market Capitalization

$996.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07

Frequently Asked Questions

What sell-side analysts currently cover shares of InnovAge?

The following equities research analysts have issued stock ratings on InnovAge in the last twelve months: Barclays PLC, Citigroup Inc., JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for INNV.

What is the current price target for InnovAge?

6 Wall Street analysts have set twelve-month price targets for InnovAge in the last year. Their average twelve-month price target is $6.65, suggesting a possible downside of 9.5%. JPMorgan Chase & Co. has the highest price target set, predicting INNV will reach $10.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $3.90 for InnovAge in the next year.
View the latest price targets for INNV.

What is the current consensus analyst rating for InnovAge?

InnovAge currently has 1 sell rating and 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INNV, but not buy more shares or sell existing shares.
View the latest ratings for INNV.

What other companies compete with InnovAge?

Other companies that are similar to InnovAge include Sharecare, U.S. Physical Therapy, The Pennant Group, CRH Medical and Pear Therapeutics. Learn More about companies similar to InnovAge.

How do I contact InnovAge's investor relations team?

InnovAge's physical mailing address is 8845 Rehco Road, San Diego CA, 92121. The company's listed phone number is 844-803-8745 and its investor relations email address is [email protected] The official website for InnovAge is www.innovuspharma.com. Learn More about contacing InnovAge investor relations.